TP508 & Covid-19

A single injection of TP508 24 hours after SARS-CoV-2 infection almost completely blocks the viral-induced cytokine storm including upregulation of IL6 and TNFa) in animals expressing the human ACE2 receptor. Thus, TP508 reduces inflammation which mitigates vascular effects of SARS-CoV-2 leading to disease progression, allowing for earlier patient recovery.

Other preclinical studies show that TP508 can prevent vascular changes that are associated with COVID-19 progression.

  • TP508 attenuates neuroinflammation and blood barrier changes induced by radiotherapy and traumatic brain injury.
  • TP508 reverses ischemic effects in the heart following acute myocardial infarct
  • TP508 reduces radiation-induced coagulopathy and hemorrhage in brain, heart and lungs to prevent multiple organ failure.